Withdrawal of Sitaxentan (Thelin) Creates Huge Unmet Need in the Pulmonary Arterial Hypertension (PAH) Market


February 4, 2011
5 Pages - SKU: GBDT6112156
License type:
Withdrawal of Sitaxentan (Thelin) Creates Huge Unmet Need in the Pulmonary Arterial Hypertension (PAH) Market

Summary

GlobalData’s report, “Withdrawal of Sitaxentan (Thelin) Creates Huge Unmet Need in the Pulmonary Arterial Hypertension (PAH) Market” provides key data, information on PAH Market.

Scope
  • Data and information on noval therapy on PAH market
Reasons to buy
  • Develop business strategies by understanding the trends and developments in PAH Market



More Drug Discovery reports by GlobalData

Inflammatory Pain Global Clinical Trials Review, H1, 2013 by GlobalData
Inflammatory Pain Global Clinical Trials Review, H1, 2013SummaryGlobalData's clinical trial report, “Inflammatory Pain Global Clinical Trials Review, H1, 2013 provides data on the Inflammatory Pain ...
Cancer Pain Global Clinical Trials Review, H1, 2013 by GlobalData
Cancer Pain Global Clinical Trials Review, H1, 2013SummaryGlobalData's clinical trial report, “Cancer Pain Global Clinical Trials Review, H1, 2013 provides data on the Cancer Pain ...
Ascites Global Clinical Trials Review, H1, 2013 by GlobalData
Ascites Global Clinical Trials Review, H1, 2013SummaryGlobalData's clinical trial report, “Ascites Global Clinical Trials Review, H1, 2013 provides data on the Ascites clinical trial scenario. ...
OpportunityAnalyzer: Cystic Fibrosis Therapeutics - Opportunity Analysis and Forecasts to 2017 by GlobalData
OpportunityAnalyzer: Cystic Fibrosis Therapeutics - Opportunity Analysis and Forecasts to 2017SummaryCystic Fibrosis (CF) is an autosomal recessive disease characterized by the secretion of thick, sticky ...
See all reports like this >>